Welcome to our dedicated page for Actuate Therapeutics SEC filings (Ticker: ACTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elraglusib’s journey from lab bench to clinic means Actuate Therapeutics’ SEC disclosures are packed with dense data on GSK-3β science, trial cohorts, and cash runway projections—details critical for biotech investors yet hard to digest quickly.
Problem: Finding the latest dose-limiting toxicity update inside a 300-page 10-K or spotting a sudden insider stock sale before a Phase 2 read-out can take hours. Solution: Stock Titan’s AI-powered platform turns every Actuate Therapeutics filing into an executive-level brief. Our engine highlights clinical-trial milestones, R&D spend, and partnership terms, then links them to market-moving events.
Access every document the moment it hits EDGAR: 10-K annual reports, 10-Q quarterly earnings, 8-K material events, S-1 fundraising prospectuses, and real-time Form 4 insider trades. Investors searching for “Actuate Therapeutics insider trading Form 4 transactions” or “Actuate Therapeutics quarterly earnings report 10-Q filing” land here because we answer those questions directly. Want the proxy statement executive compensation breakdown? It’s parsed and summarised. Need “Actuate Therapeutics 8-K material events explained”? Our AI does that, too.
Practical use cases include:
- Monitoring “Actuate Therapeutics Form 4 insider transactions real-time” to gauge management sentiment.
- Reviewing “Actuate Therapeutics earnings report filing analysis” to compare cash burn across quarters.
- Downloading an “Actuate Therapeutics annual report 10-K simplified” to understand pipeline risk factors without legalese.
Actuate Therapeutics, Inc. filed an 8-K reporting that it has launched an offering of common stock and executed an underwriting agreement with Lucid Capital Markets, LLC. The filing lists two press releases: one announcing the launch of the offering dated
Actuate Therapeutics, Inc. (ACTU) is offering common stock at a public offering price of $7.00 per share, with underwriting discounts of $0.49 per share. Proceeds before expenses are shown as $6.51 per share, totaling $13,950,006 (or $16,042,502 if the underwriter exercises the over-allotment option). After the offering the company expects approximately 2,142,858 shares outstanding (2,464,286 if over-allotment exercised). The prospectus discloses a going concern financing risk and warns that additional equity or debt may be unavailable or dilutive. The filing lists reserved shares, outstanding options and warrants and describes customary lock-up periods of 90 and 75 days and typical underwriting and distribution terms.
Actuate Therapeutics, Inc. (ACTU) prospectus supplement describes an offering of common stock and related securities and discloses financing, dilution and operational risks. The document states lock-up agreements restricting insider sales for 90 days and an underwriting-related 75-day restriction. It lists share counts reserved or issuable as of June 30, 2025 and September 5, 2025, including restricted stock units, outstanding options (1,774,477 as of June 30, 2025), warrants exercisable for 922,096 shares at a weighted average exercise price of $7.87, and multiple amounts reserved under a Committed Equity Facility with B. Riley (3,364,407 as of September 5, 2025; 3,647,945 as of June 30, 2025). The supplement highlights material risks: substantial doubt about the company’s ability to continue as a going concern, the need for additional capital, potential dilution to existing holders, and clinical, regulatory and market risks related to elraglusib and other product candidates. The prospectus incorporates prior SEC reports and exhibits for further detail.
Actuate Therapeutics, Inc. (ACTU) filed a Form S-3 shelf registration prospectus that describes the types of securities it may offer, including common stock, debt securities, warrants and units, and summarizes the general terms and procedures that will govern future offerings. The document repeatedly states that specific terms—such as aggregate offering amounts, prices, interest or dividend rates, maturities, conversion or exercise mechanics, redemption and default provisions, trustee rights, and fees—will be provided in an applicable prospectus supplement or in exhibits to the registration statement. The prospectus also references incorporated reports and exhibits for further detail and includes officer and director signatures attesting to the filing.
FAQ
What is the current stock price of Actuate Therapeutics (ACTU)?
What is the market cap of Actuate Therapeutics (ACTU)?
